News headlines about Derma Sciences (NASDAQ:DSCI) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Derma Sciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 44.747499401913 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-derma-sciences-nasdaqdsci-stock-price-updated.html.

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Stock Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related stocks with our FREE daily email newsletter.